On June 5, 2015, U.S. news headlines proclaimed “FDA Panel Endorses Female Viagra.” This was inaccurate, because after two denials, it was only the advisory committee to the Food and Drug Administration (FDA) who voted favorably to recommend that the FDA approve the drug Flibanserin® in August. The FDA wants more information on side effects of the drug, including dizziness, nausea, fatigue, insomnia, and the effects of alcohol. Flibanserin® is touted as a treatment for Hypoactive Sexual Desire Disorder (HSDD) for premenopausal women, which is defined as the persistent lack of sexual fantasies and desire that is distressful to the individual. An estimated 10% of women experience this distress, which is why these headlines caught most people’s attention.